Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gruber

Showing results (321-330 of 355) with videos related to

Pageof 36
Sort By:
The New England Journal of Medicine|June 22, 2022
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge StudyBeate Schmoele-Thoma, Agnieszka M Zareba, Qin Jiang, et al.
The Pediatric Infectious Disease Journal|December 1, 2016
Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term InfantsFederico Martinón-Torres, Jacek Wysocki, Kimberly J Center, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2023
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-OldsLisa Usdan, Sohil Patel, Hector Rodriguez, et al.
The Pediatric Infectious Disease Journal|June 29, 2007
Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in AsiaJohn S Tam, Maria Rosario Z Capeding, Lucy Chai See Lum, et al.
Journal of Medicinal Chemistry|December 28, 2002
Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)Allan Wissner, Elsebe Overbeek, Marvin F Reich, et al.
Nature Communications|November 23, 2024
BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosisRoss C Gruber, Gregory S Wirak, Anna S Blazier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2023
Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical TrialHamid Hassanzadeh, James Baber, Elizabeth Begier, et al.
Scientific Reports|January 14, 2023
Optimizing variant-specific therapeutic SARS-CoV-2 decoys using deep-learning-guided molecular dynamics simulationsKatharina Köchl, Tobias Schopper, Vedat Durmaz, et al.
Pediatric Blood & Cancer|March 27, 2015
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 studyMariane De Montalembert, Miguel R Abboud, Anne Fiquet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 24, 2024
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile InfectionCurtis J Donskey, Erik R Dubberke, Nicola P Klein, et al.
Pageof 36

Showing results (321-330 of 355) with videos related to

Sort By:
Pageof 36
The New England Journal of Medicine|June 22, 2022
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge StudyBeate Schmoele-Thoma, Agnieszka M Zareba, Qin Jiang, et al.
The Pediatric Infectious Disease Journal|December 1, 2016
Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term InfantsFederico Martinón-Torres, Jacek Wysocki, Kimberly J Center, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2023
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-OldsLisa Usdan, Sohil Patel, Hector Rodriguez, et al.
The Pediatric Infectious Disease Journal|June 29, 2007
Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in AsiaJohn S Tam, Maria Rosario Z Capeding, Lucy Chai See Lum, et al.
Journal of Medicinal Chemistry|December 28, 2002
Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)Allan Wissner, Elsebe Overbeek, Marvin F Reich, et al.
Nature Communications|November 23, 2024
BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosisRoss C Gruber, Gregory S Wirak, Anna S Blazier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2023
Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical TrialHamid Hassanzadeh, James Baber, Elizabeth Begier, et al.
Scientific Reports|January 14, 2023
Optimizing variant-specific therapeutic SARS-CoV-2 decoys using deep-learning-guided molecular dynamics simulationsKatharina Köchl, Tobias Schopper, Vedat Durmaz, et al.
Pediatric Blood & Cancer|March 27, 2015
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 studyMariane De Montalembert, Miguel R Abboud, Anne Fiquet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 24, 2024
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile InfectionCurtis J Donskey, Erik R Dubberke, Nicola P Klein, et al.
Pageof 36